Emcure Pharma IPO Details
The Emcure Pharma IPO is a book build issue with a total issue size of ₹1952.03 cr, comprising of fresh issue of 7936507 equity shares., and a offer for sale of 11428839 equity shares. Emcure Pharma IPO opened for subscription on Jul 03, 2024 and closed on Jul 05, 2024. Emcure Pharma IPO is set price band at ₹960 to ₹1008 per share, with a lot size of 14 shares. Minimum investment for Retail investors was ₹14,112.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Jul 08, 2024, and listed on both the NSE and BSE on Jul 10, 2024.
MUFG Intime India Private Limited has been appointed as the registrar. Axis Capital Limited, J.P. Morgan India Private Limited, Kotak Mahindra Capital Company Limited and Jefferies India Private Limited are the Book Running Lead Manager for the issue.
Before investing in the Emcure Pharma IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 960 – 1008
- Lot Size
- 14
- Issue Size
- ₹1952.03 Cr
- Minimum Investment
- ₹14112 (14 Shares)
- Listing Date
- 10 July 2024
Current GMP
₹0 (0.00%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Emcure Pharmaceuticals Limited
Incorporated in 1981, Emcure Pharmaceuticals Limited is a prominent Indian pharmaceutical company that develops, manufactures, and globally markets a diverse range of pharmaceutical products across several major therapeutic areas.
As of September 2023, Emcure ranks 13th in domestic sales among Indian pharmaceutical companies and holds the 4th largest market share in its covered markets. The company has led the gynaecology and HIV antiviral therapeutic areas for the same period.
In the first half of FY 2023, sales in India accounted for 50.84% of Emcure's total revenue, while for the entire FY 2023, this figure was 53.16%. Between September 2019 and September 2023, Emcure’s domestic sales grew at a CAGR of 10.80%, surpassing the overall growth of the Indian pharmaceutical market.
Emcure employs 552 scientists and operates five research facilities in India, having filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. The company boasts 201 granted patents, 33 pending applications, and 102 drug master files.
The company's 13 manufacturing facilities in India produce a variety of pharmaceutical and biopharmaceutical products. Its marketing and distribution network in India is supported by over 5,000 field personnel and stockists, served by 37 carry-and-forward agents, ensuring a robust interaction with healthcare providers nationwide.
Peer Details
The companies considered by Emcure Pharmaceuticals as its peers include:
- Dr. Reddy's Laboratories Limited
- Cipla Limited
- Alkem Laboratories Limited
- Torrent Pharmaceuticals Limited
- Mankind Pharma Limited
- Abbott India Limited
- J. B. Chemicals & Pharmaceuticals Limited
Emcure Pharma IPO Promoters
- Satish Mehta
- Sunil Mehta
Promoters Holding
Holding Pre Issue
98.90%
Holding Post Issue
78.24%
Emcure Pharma IPO Objective
The company plans to allocate the net proceeds from the issuance to the following purposes:
- Repayment and/or prepayment of certain outstanding borrowings.
- General corporate purposes.
Address / Contact Info
Emcure Pharmaceuticals Limited
Plot No. P-1 and P-2,
IT-BT Park, Phase II, M.I.D.C.,
Hinjawadi, Pune -411 057
Phone: +91 20 3507 0033
Email: investors@emcure.co.in
Website: https://www.emcure.com
IPO Snapshot
Book Running Lead Managers
- Axis Capital Limited
- J.P. Morgan India Private Limited
- Kotak Mahindra Capital Company Limited
- Jefferies India Private Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Emcure Pharma IPO is a Book-building IPO with a total issue size of ₹1952.03 crore. The Emcure Pharma IPO price band is ₹960 to 1008 per share. The Emcure Pharma IPO subscription opens on Wed, Jul 3, 2024, and closes on Fri, Jul 5, 2024. The Emcure Pharma IPO will be listed on the BSE,NSE. MUFG Intime India Private Limited is the registrar for the Emcure Pharma IPO.
The Emcure Pharma IPO opens on Wed, Jul 3, 2024 and closes on Fri, Jul 5, 2024
Emcure Pharma IPO Price Band is ₹960 to 1008 per share.
Emcure Pharma IPO lot size is 14 shares, Retail investors need a minimum investment of ₹14112 based on the upper price band
The minimum investment for Emcure Pharma IPO is ₹14112, based on one lot of 14 shares at the upper price band of ₹1008 per share.
Investors can apply for the Emcure Pharma IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Jul 5, 2024. The application amount remains blocked until the Emcure Pharma IPO allotment is finalized.
Emcure Pharma IPO issue size is ₹1952.03 crores.
Emcure Pharma IPO allotment date is Wed, Jul 1, 2026.
The registrar for Emcure Pharma IPO is MUFG Intime India Private Limited. Investors can go to MUFG Intime India Private Limited website to check Emcure Pharma IPO allotment status, refund processing, and other IPO-related information.
The Emcure Pharma IPO GMP (Grey Market Premium) is ₹300 as of Wed, Jul 10, 2024. Based on the upper price band of ₹1008 per share, the estimated Emcure Pharma IPO listing price is ₹1308, indicating a potential listing gain of approximately 0% over the issue price.